MedaSorb Technologies Corporation reported earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company had loss of $841,058 against $862,751 reported a year ago. For the nine months period, the company reported loss of $2,453,154 against $2,364,478 for the same period a year ago. Historically, the company's losses have resulted principally from costs incurred in the research and development of its polymer technology, and general and administrative expenses, which together were $740,107 and $2,231,227 for the three and nine month periods ended September 30, 2009 and $755,021 and $2,055,468 for three and nine month periods ended September 30, 2008.

MedaSorb Technologies Corporation - Conference Presentation Calls

Fresenius Medical Care North America and Fresenius USA Marketing Inc. announced the closing of a distribution and supply agreement with Advanced Renal Technologies Inc. (MedaSorb Technologies Corporation). This agreement grants U.S. supply and distribution rights to Fresenius USA Marketing Inc., for CITRASATE(R) and DRYalysate(R), citrate dialysate for hemodialysis for the End Stage Renal Disease patient population. Dialysate is utilized during the performance of hemodialysis. The bi-directional movement of molecules between blood and dialysate across a semi-permeable membrane (dialyzers) removes toxins and wastes from the bloodstream while instilling the patient with valuable replacement molecules like bicarbonate. CITRASATE(R) utilizes citric acid, a known anticoagulant, rather than traditional acetic acid, to regulate dialysate pH. Unlike traditional acetic acid, citric acid may provide a local anticoagulant effect at the dialysis membrane during hemodialysis. Initial clinical findings suggest decreased utilization of heparin anticoagulant therapy during hemodialysis using citrate dialysate, as well as increased delivered dialysis dose.